CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

Despite weak Q3 earnings, Bharat Petroleum (BPCL) draws attention from global brokerages. CLSA upgraded BPCL to ‘Hold’ with a ...

The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...

CLSA has included Zomato in its High Conviction Outperform list, maintaining an "Overweight" rating and increasing the target ...

CLSA has initiated coverage on Hyundai Motor India with an 'Outperform' rating and a target price of Rs 2,155, citing strong ...

Vikash Kumar Jain, India Strategist and Head of Research at CLSA, predicts 2025 will be a year of consolidation for Indian markets. He noted that the consolidation trend, which began in October, could ...

Finance companies' performance in the first half of 2025 is expected to be impacted by high credit costs due to unsecured credit. But it is seen normalising in the second half on underwriting ...

Shares of most staples companies in India, from HUL, to Nestle India to ITC, or even Avenue Supermarts, have corrected between 20% to 30% from their peak so far.

The brokerage firm has also added Zomato to its high conviction outperform list, saying the recent correction is a buying ...

Bank Mandiri (IDX: BMRI) is projected to become Indonesia’s most profitable bank by 2025, surpassing Bank Rakyat Indonesia ...